Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493789 · ClinicalTrials.gov registry record · Phase 1
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03493789 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 19 participants.
The verdict
NCT03493789, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.
Interventions
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Fludeoxyglucose F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-04-13 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03493789
The ClinicalTrials.gov registry entry for NCT03493789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT03493789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03493789 about?
NCT03493789 is a clinical study titled "Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy". This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the stan...
What is the current status of trial NCT03493789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-04-13. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT03493789?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (RADIATION), Positron Emission Tomography (PET) (PROCEDURE), Fludeoxyglucose F-18 (DRUG).
Who is sponsoring clinical trial NCT03493789?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.